Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David G Bostwick

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
Scandinavian Journal of Urology and Nephrology. Supplementum|July 16, 2005
Epidemiology and statistical methods in prediction of patient outcomeDavid G Bostwick, Jan Adolfsson, Harry B Burke, et al.
Urology|May 7, 2002
Needle core length in sextant biopsy influences prostate cancer detection rateKenneth A Iczkowski, George Casella, R John Seppala, et al.
Nutrients|December 4, 2012
Prostatic response to supranutritional selenium supplementation: comparison of the target tissue potency of selenomethionine vs. selenium-yeast on markers of prostatic homeostasisDavid J Waters, Shuren Shen, Seema S Kengeri, et al.
The American Journal of Surgical Pathology|December 6, 2003
Adenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 casesKenneth A Iczkowski, Kevin L Ferguson, David D Grier, et al.
Human Pathology|October 17, 2003
Subvisual changes in chromatin organization state are detected by karyometry in the histologically normal urothelium in patients with synchronous papillary carcinomaRodolfo Montironi, Marina Scarpelli, Roberta Mazzucchelli, et al.
The Journal of Urology|July 14, 2015
Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate BiopsyDaniel M Moreira, David G Bostwick, Gerald L Andriole, et al.
Cancers|September 27, 2025
First-in-Human Phase II Clinical Trial of Multiplex IntraTumoral Immunotherapy (MITI) in Patients with Metastatic Solid Cancer (Abscopal 5001 Trial)David G Bostwick, Melanie M Wilk, Brian R Bostwick, et al.
Carcinogenesis|April 9, 2005
Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine modelDavid J Waters, Shuren Shen, Lawrence T Glickman, et al.
The Journal of Urology|August 18, 2004
Phyllodes tumor of the prostate: long-term followup study of 23 casesDavid G Bostwick, Deloar Hossain, Junqi Qian, et al.
Urology|February 19, 2008
Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancerKenneth A Iczkowski, Deloar Hossain, Kathleen C Torkko, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Scandinavian Journal of Urology and Nephrology. Supplementum|July 16, 2005
Epidemiology and statistical methods in prediction of patient outcomeDavid G Bostwick, Jan Adolfsson, Harry B Burke, et al.
Urology|May 7, 2002
Needle core length in sextant biopsy influences prostate cancer detection rateKenneth A Iczkowski, George Casella, R John Seppala, et al.
Nutrients|December 4, 2012
Prostatic response to supranutritional selenium supplementation: comparison of the target tissue potency of selenomethionine vs. selenium-yeast on markers of prostatic homeostasisDavid J Waters, Shuren Shen, Seema S Kengeri, et al.
The American Journal of Surgical Pathology|December 6, 2003
Adenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 casesKenneth A Iczkowski, Kevin L Ferguson, David D Grier, et al.
Human Pathology|October 17, 2003
Subvisual changes in chromatin organization state are detected by karyometry in the histologically normal urothelium in patients with synchronous papillary carcinomaRodolfo Montironi, Marina Scarpelli, Roberta Mazzucchelli, et al.
The Journal of Urology|July 14, 2015
Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate BiopsyDaniel M Moreira, David G Bostwick, Gerald L Andriole, et al.
Cancers|September 27, 2025
First-in-Human Phase II Clinical Trial of Multiplex IntraTumoral Immunotherapy (MITI) in Patients with Metastatic Solid Cancer (Abscopal 5001 Trial)David G Bostwick, Melanie M Wilk, Brian R Bostwick, et al.
Carcinogenesis|April 9, 2005
Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine modelDavid J Waters, Shuren Shen, Lawrence T Glickman, et al.
The Journal of Urology|August 18, 2004
Phyllodes tumor of the prostate: long-term followup study of 23 casesDavid G Bostwick, Deloar Hossain, Junqi Qian, et al.
Urology|February 19, 2008
Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancerKenneth A Iczkowski, Deloar Hossain, Kathleen C Torkko, et al.
Pageof 12